CHICAGO, May 27, 2024
/PRNewswire/ -- Preclinical Imaging Market in terms of
revenue was estimated to be worth $946
million in 2024 and is poised to reach $1,259 million by 2029, growing at a CAGR of 5.9%
from 2024 to 2029 according to a new report by
MarketsandMarkets™.
The growth in the preclinical imaging market is driven by the
increasing funding to support preclinical research, development of
low-cost & affordable preclinical imaging systems, and
increasing market demand for new drug development and non-invasive
small-animal imaging techniques.
Download an Illustrative overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841
Browse in-depth TOC on "Preclinical Imaging Market"
83 - Tables
40 - Figures
165 -
Pages
Preclinical Imaging Market Scope:
Report
Coverage
|
Details
|
Market Revenue in
2024
|
$946 million
|
Estimated Value by
2029
|
$1,259
million
|
Growth Rate
|
Poised to grow at a
CAGR of 5.9%
|
Market Size Available
for
|
2018–2029
|
Forecast
Period
|
2024–2029
|
Forecast
Units
|
Value (USD
Million)
|
Report
Coverage
|
Revenue Forecast,
Competitive Landscape, Growth Factors, and Trends
|
Segments
Covered
|
Product Type,
Application, End User, and Region
|
Geographies
Covered
|
North America (US,
Canada), Europe (Germany, France, UK, Italy, Spain, and the Rest of
Europe), Asia Pacific (Japan, China, India, and the Rest of Asia
Pacific), Latin America (Brazil, Mexico, And Rest of Latin
America), and Middle East & Africa (GCC Countries, and Rest of
MEA)
|
Report
Highlights
|
Updated financial
information / product portfolio of players
|
Key Market
Opportunities
|
Increasing Adoption of
Imaging Systems for Preclinical Purposes
|
Key Market
Drivers
|
Increasing market
demand for non-invasive small animal imaging techniques
|
Optical Imaging reagents segment is the largest product type
of the preclinical reagents market in 2023.
Based on reagents, the preclinical imaging market is segmented
into optical imaging reagents, nuclear imaging reagents, MRI
contrast agents, ultrasound contrast agents, and CT contrast
agents. Among these, optical imaging reagents segment
accounted for the largest share of the preclinical imaging market
in 2023. The large market share of the optical imaging reagents
segment is attributed to the high penetration of optical imaging
modalities in preclinical research studies
Oncology segment is the largest application of the
preclinical imaging market in 2023.
Based on application, the preclinical imaging market is
segmented into oncology, cardiology, neurology, infectious
diseases, immunology and inflammation, and other applications. In
2023, oncology segment accounted for the largest share of the
market. This can be due to as oncology benefits greatly from
advancements in molecular imaging, allowing researchers to target
specific biomarkers associated with cancer cells. This provides
valuable insights into tumour biology and drug targeting.
By end user, pharmaceutical & biotechnology companies are
the largest end user in the brain preclinical imaging market in
2023.
Based on end user, the preclinical imaging market is segmented
into pharmaceutical & biotechnology companies, academic and
research centers, imaging centers, and other end users. In 2023,
the pharmaceutical & biotechnology companies segment accounted
for the largest share in the market. The volume of research and
development work conducted by these companies has increased
significantly, accompanied by a rise in investment for these
activities. The ongoing need for advanced drugs will continue to
drive demand for research and development efforts. Biotechnology
companies utilize this technology extensively due to its wide range
of applications.
North America dominates the
global preclinical imaging market in 2023.
The preclinical imaging market is segmented into five major
regional segments, namely, North
America, Europe,
Asia Pacific, Latin America and Middle East and Africa. North
America is anticipated to dominate the preclinical imaging
market due to its developed infrastructure, numerous preclinical
projects, and higher adoption rates of advanced technological
devices in the region.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=841
Preclinical Imaging Market Dynamics:
Drivers:
1. Increasing market demand for non-invasive small animal
imaging techniques
Restraints:
1. Strict regulations governing preclinical research
Opportunities:
1. Increasing Adoption of Imaging Systems for Preclinical
Purposes
Challenge:
1. Technological and procedural limitations associated
with standalone preclinical imaging systems
Key Market Players of Preclinical Imaging
Industry:
Prominent players in the preclinical imaging market include MR
Solutions (UK), Mediso Ltd. (UK), Sofie (US), Fujifilm Visual
Sonics (Canada), MILABS B.V.
(Netherlands), Aspect Imaging
Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK),
Viewworks (Korea), Kub Technologies (US), Medikor (US), Trifoil
Imaging (US), IVIM Technology Corp. (South Korea), Cubresa, Inc. (Canada), Berthold Technologies GMBH &
CO.KG (Germany), Miltenyi Biotech
GmbH (Germany), AI4R (France), Bruker Corporation (US), and Revvity,
Inc. (US).
Breakdown of the supply-side, demand side, primary interviews
by company type, designation, and region:
- By Supply Side: Tier 1 (25%), Tier 2 (5%), and Tier 3
(70%)
- By Designation: C-level Executives (27%), Director-level (18%),
and Others (55%)
- By Region: North America
(40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East and Africa (5%)
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=841
Preclinical Imaging Market - Key Benefits of Buying the
Report:
The report can help established firms as well as new
entrants/smaller firms to gauge the pulse of the market, which, in
turn, would help them garner a greater share. Firms purchasing the
report could use one or a combination of the below-mentioned five
strategies.
This report provides insights into the following
pointers:
- Analysis of key drivers (technological advancements in the
field of molecular imaging, increasing market demand for
noninvasive small-animal imaging techniques, growing number of
public-private initiatives and funding to support preclinical
researches, and development of low-cost & affordable
preclinical imaging systems), restraints (strict regulation,
significant installation and operational cost ), opportunities
(expansion in emerging markets, and increasing demand for
non-invasive techniques) and challenge (Technological and
procedural limitations associated with standalone preclinical
imaging systems)
- Product Development/Innovation: Detailed insights on upcoming
technologies, research and development activities, and product
launches in the preclinical imaging market.
- Market Development: Comprehensive information about lucrative
emerging markets. The report analyzes the markets for various types
of preclinical imaging solutions across regions.
- Market Diversification: Exhaustive information about solutions,
untapped regions, recent developments, and investments in the
preclinical imaging market.
- Competitive Assessment: In-depth assessment of market shares,
strategies, products, distribution networks, and manufacturing
capabilities of the leading players in the preclinical imaging
market.
Related Reports:
Mice Model Market - Global Forecasts to 2029
Contrast Media Market - Global Forecasts to 2029
Diagnostic Imaging Market - Global Forecasts to
2028
Clinical Trial Imaging Market - Global Forecasts to
2028
eClinical Solutions Market - Global Forecasts to
2027
Get access to the latest updates on Preclinical Imaging
Companies and Preclinical Imaging Industry
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish
Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.com/news-releases/preclinical-imaging-market-worth-1-259-million--marketsandmarkets-302155874.html
SOURCE MarketsandMarkets